Cyclin e expression and prognosis in breast cancer patients: a meta-analysis of published studies.
In vitro studies showed that cyclin E can accelerate the cell cycle by shorten the G1/S phase transition. Therefore, varieties of studies have investigated the relationship between cyclin E and survival in breast cancer patients. However, the results differed widely between studies. We reviewed the published studies and performed a meta-analysis, which including 12 independent studies and 2,534 patients. The combined HR estimate for relapse-free survival (RFS) was 2.32 (95% CI, 1.25-4.30) and 1.72 (95% CI, 0.95-3.10) in univariate and multivariate analysis, respectively. In addition, the combined HR estimate for overall survival (OS) and breast cancer specific survival (BCSS) was 2.98 (95% CI, 1.85-4.78) and 2.86 (95% CI, 1.85-4.41) in univariate and multivariate analysis, respectively. In conclusion, the high level of cyclin E appears to be an independent prognostic factor to OS/BCSS of breast cancer patients but not to RFS.
Wang
Lei
L
Department of Breast Surgery, Department of Oncology, Cancer Hospital/Cancer Institute, Fudan University, Shanghai, China.
Shao
Zhi-Ming
ZM
D001943:Breast Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D019927:Cyclin E / Q000235:genetics / Q000378:metabolism*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000502:physiology; D006801:Humans; D011379:Prognosis; D012333:RNA, Messenger / Q000378:metabolism; D015996:Survival Rate
D019927:Cyclin E; D012333:RNA, Messenger